Targeted therapy of chronic myeloid leukemia
نویسندگان
چکیده
منابع مشابه
Chronic Myeloid Leukemia: A Paradigm of Successful Targeted Therapy
Chronic myeloid leukemia (CML) is commonest type of chronic leukemia in India. It has achieved enormous attention in the medical literature because of the delineation of its molecular basis and the discovery of successful targeted therapy in the form of tyrosine kinase inhibitor, imatinib. Chronic myeloid leukemia is defined as a myeloproliferative disease that originates in an abnormal pleurip...
متن کاملTargeted chronic myeloid leukemia therapy: Seeking a cure.
PURPOSE This article focuses on imatinib, how it has altered CML therapy, clinical trials that are the basis for its efficacy, and adverse effects associated with its current clinical use. SUMMARY Maintaining patients with CML in chronic phase (CP) yields the prospect of improved long-term survival. As recently as 1993, CML was limited to treatment with standard cytoreductive therapies. These...
متن کاملEvaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia
Background: Imatinib mesylate is the first generation of Tyrosine kinase inhibitors (TKI) and highly effective in the treatment of chronic myeloid leukemia (CML). We aimed to evaluate thyroid function at baseline and at 1, 3, 6 and 12 months after initiation of Imatinib mesylate therapy in 20 newly diagnosed BCR-ABL positive CML patients. Methods: This study was done during 2013-2014, 20 new c...
متن کاملModern Therapy of Chronic Myeloid Leukemia
Chronic myeloid leukemia is one of the most thoroughly studied and, undoubtedly, best understood neoplasms. There are about 4000 and 5000 new cases of CML every year in the USA. CML is a hematologic stem cell malignancy that typically evolves in 3 distinct clinical stages: chronic and accelerated phases and blast crisis. The chronic phase lasts several years and is characterized by accumulation...
متن کاملTargeted treatment of chronic myeloid leukemia: role of imatinib
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of pleuripotent hematopoetic stem cells. The incidence of CML is 1 to 2 cases per 100,000 people per year; in the Western Hemisphere, CML accounts for 15% of leukemias in adults. Discovery of the specific karyotypic abnormality of the Philadelphia (Ph) chromosome in the pathogenesis of CML has led ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biochemical Pharmacology
سال: 2010
ISSN: 0006-2952
DOI: 10.1016/j.bcp.2010.05.001